Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Valentina Boni

Showing results (21-30 of 63) with videos related to

Pageof 7
Sort By:
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|October 6, 2021
Doxorubicin plus lurbinectedin in patients with advanced endometrial cancer: results from an expanded phase I studyRebecca Kristeleit, Victor Moreno, Valentina Boni, et al.
European Journal of Cancer (Oxford, England : 1990)|August 27, 2023
Pooled Safety Analysis of Single-Agent Lurbinectedin in Patients With Advanced Solid TumoursAlexandra Leary, Ana Oaknin, José Manuel Trigo, et al.
Nature Medicine|July 31, 2025
Precemtabart tocentecan, an anti-CEACAM5 antibody-drug conjugate, in metastatic colorectal cancer: a phase 1 trialScott Kopetz, Valentina Boni, Ken Kato, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 4, 2021
Phase I, First-in-Human Study of the Probody Therapeutic CX-2029 in Adults with Advanced Solid Tumor MalignanciesMelissa Johnson, Anthony El-Khoueiry, Navid Hafez, et al.
Journal for Immunotherapy of Cancer|September 20, 2017
Phase 1 study of intravenous administration of the chimeric adenovirus enadenotucirev in patients undergoing primary tumor resectionRocio Garcia-Carbonero, Ramon Salazar, Ignacio Duran, et al.
Journal for Immunotherapy of Cancer|July 24, 2021
CX-072 (pacmilimab), a Probody PD-L1 inhibitor, in combination with ipilimumab in patients with advanced solid tumors (PROCLAIM-CX-072): a first-in-human, dose-finding studyRachel E Sanborn, Omid Hamid, Elisabeth Ge de Vries, et al.
Molecular Cancer Therapeutics|October 14, 2025
Dabogratinib (TYRA-300), an FGFR3 isoform-selective inhibitor: preclinical and initial clinical evidence of anti-tumor activityJacqueline H Starrett, Eric L Allen, Melissa Neal, et al.
Cancer Chemotherapy and Pharmacology|October 27, 2020
Effect of lurbinectedin on the QTc interval in patients with advanced solid tumors: an exposure-response analysisSalvador Fudio, Josep Tabernero, Vivek Subbiah, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 20, 2022
First-in-Human Dose-Escalation Study of Cyclin-Dependent Kinase 9 Inhibitor VIP152 in Patients with Advanced Malignancies Shows Early Signs of Clinical EfficacyJennifer R Diamond, Valentina Boni, Emerson Lim, et al.
Future Oncology (London, England)|June 29, 2023
A plain language summary of results from the GARNET study of dostarlimab in patients with endometrial cancerAna Oaknin, Lucy Gilbert, Anna V Tinker, et al.
Pageof 7

Showing results (21-30 of 63) with videos related to

Sort By:
Pageof 7
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|October 6, 2021
Doxorubicin plus lurbinectedin in patients with advanced endometrial cancer: results from an expanded phase I studyRebecca Kristeleit, Victor Moreno, Valentina Boni, et al.
European Journal of Cancer (Oxford, England : 1990)|August 27, 2023
Pooled Safety Analysis of Single-Agent Lurbinectedin in Patients With Advanced Solid TumoursAlexandra Leary, Ana Oaknin, José Manuel Trigo, et al.
Nature Medicine|July 31, 2025
Precemtabart tocentecan, an anti-CEACAM5 antibody-drug conjugate, in metastatic colorectal cancer: a phase 1 trialScott Kopetz, Valentina Boni, Ken Kato, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 4, 2021
Phase I, First-in-Human Study of the Probody Therapeutic CX-2029 in Adults with Advanced Solid Tumor MalignanciesMelissa Johnson, Anthony El-Khoueiry, Navid Hafez, et al.
Journal for Immunotherapy of Cancer|September 20, 2017
Phase 1 study of intravenous administration of the chimeric adenovirus enadenotucirev in patients undergoing primary tumor resectionRocio Garcia-Carbonero, Ramon Salazar, Ignacio Duran, et al.
Journal for Immunotherapy of Cancer|July 24, 2021
CX-072 (pacmilimab), a Probody PD-L1 inhibitor, in combination with ipilimumab in patients with advanced solid tumors (PROCLAIM-CX-072): a first-in-human, dose-finding studyRachel E Sanborn, Omid Hamid, Elisabeth Ge de Vries, et al.
Molecular Cancer Therapeutics|October 14, 2025
Dabogratinib (TYRA-300), an FGFR3 isoform-selective inhibitor: preclinical and initial clinical evidence of anti-tumor activityJacqueline H Starrett, Eric L Allen, Melissa Neal, et al.
Cancer Chemotherapy and Pharmacology|October 27, 2020
Effect of lurbinectedin on the QTc interval in patients with advanced solid tumors: an exposure-response analysisSalvador Fudio, Josep Tabernero, Vivek Subbiah, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 20, 2022
First-in-Human Dose-Escalation Study of Cyclin-Dependent Kinase 9 Inhibitor VIP152 in Patients with Advanced Malignancies Shows Early Signs of Clinical EfficacyJennifer R Diamond, Valentina Boni, Emerson Lim, et al.
Future Oncology (London, England)|June 29, 2023
A plain language summary of results from the GARNET study of dostarlimab in patients with endometrial cancerAna Oaknin, Lucy Gilbert, Anna V Tinker, et al.
Pageof 7